December 05, 2019

TMIST Trial Gains Ground on Site and Patient Milestones

Tomosynthesis Mammographic Imaging Screening Trial (TMIST) Principal Investigator Etta Pisano, MD, FACR, shared news of progress with current and prospective TMIST site investigators at the Radiological Society of North America 2019 annual meeting.

Pisano, American College of Radiology Chief Research Officer, told attendees at sessions for prospective domestic and international sites, that nearly 90 of the planned 150 certified mammography clinics in the U.S. and abroad are now taking part in TMIST, and nearly 20,000 patients have been enrolled.

Benefits of TMIST participation, outlined in this video, have attracted interest from non-academic, community-based women’s health services, large health systems and freestanding radiology sites alike.

TMIST Principal Investigator Etta Pisano, MD, explains the benefits of TMIST participation to RSNA 2019 attendees.

“The number of women enrolled in TMIST nearly quadrupled in 2019. TMIST sites increased nearly 50 percent this year. There is room for more of both. Facilities with both digital breast tomosynthesis (DBT) and digital mammography should visit or contact TMIST staff about study participation,” said Pisano.

TMIST is the first large randomized controlled trial that seeks to identify women in which DBT may outpace two-dimensional (2D) digital mammography at reducing advanced breast cancer development. TMIST will also create the world’s largest breast cancer biorepository.

Pisano will hold informational sessions March 11–15, 2020, at the European Congress of Radiology conference in Vienna, Austria, and April 9, 2020, at the Global Breast Cancer Conference 2020 in Seoul, Korea.

Visit TMIST to find out how and why your practice should take part in the largest randomized controlled breast cancer screening trial in decades.

Email with any questions you may have about TMIST.